Sangamo Therapeutics Inc. News

Latest updates and market news for SGMO

3 news

Dec 1 - Dec 7, 2025

Page 1

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight

PR Newswire

4 days ago

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight

📈

AI Sentiment

Highly Positive

8/10

MT Newswires

5 days ago

Sangamo Therapeutics' Potential Small Fiber Neuropathy Pain Treatment Granted Fast-Track Status; Shares up Pre-Bell

📊

AI Sentiment

Positive

6/10

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

GlobeNewswire

5 days ago

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

📈

AI Sentiment

Highly Positive

8/10

Share this news page

Share on Social Networks: